Tokyo Tape
Sign in
← H.U. Group Holdings

Half-year report · Q2

4544.TEDINET S100UPH6
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥120.0bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥236.9bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥116.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥956m2024-04-01 → 2024-09-30Cons.Operating income
Operating income−¥1.6bn2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥1.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income−¥7.2bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.6bn2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥1.6bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax−¥1.6bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥821m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.6bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥821m2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥291.4bnat 2024-09-30Cons.Assets
Total assets¥290.8bnat 2024-03-31Cons.Assets
Total assets¥284.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥155.3bnat 2024-09-30Cons.Liabilities
Total liabilities¥148.3bnat 2024-03-31Cons.Liabilities
Net assets / equity¥136.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥142.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥150.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥47.0bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥39.9bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥47.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥39.9bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥37.1bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥44.2bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥16.6bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.5bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥9.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥16.1bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥10.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.8bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥6.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-14.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-132.772023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-322023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio46.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio49.0%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio52.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥2.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥76.7bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥76.5bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥205m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥2.9bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥31.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥29.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2024-04-01 → 2024-09-30¥14.5bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2024-04-01 → 2024-09-30¥14.4bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥9m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2024-04-01 → 2024-09-30¥879m
—segment totalrevenue2024-04-01 → 2024-09-30¥122.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥120.0bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.4bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.5bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥3.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥2.8bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥72.4bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥72.3bn
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥74m
jpcrp040300-q2r_E00967-000Clinical Lab Testing Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥6.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥33.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥30.2bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3.0bn
jpcrp040300-q2r_E00967-000In Vitro Diagnostics Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥6.8bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue external2023-04-01 → 2023-09-30¥14.0bn
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E00967-000Sterilization And Related Servicesreportable segmentsegment profit2023-04-01 → 2023-09-30¥564m
—segment totalrevenue2023-04-01 → 2023-09-30¥119.6bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥116.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥3.1bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥1.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 536
ItemContextValueUnit
Income taxes payablePrior1YearInstant785000000JPY
Income taxes payableCurrentQuarterInstant994000000JPY
Provision for bonusesPrior1YearInstant6109000000JPY
Provision for bonusesCurrentQuarterInstant5005000000JPY
Other clPrior1YearInstant10325000000JPY
Other clCurrentQuarterInstant11883000000JPY
Current liabilitiesPrior1YearInstant64070000000JPY
Current liabilitiesCurrentQuarterInstant67028000000JPY
Bonds payablePrior1YearInstant31100000000JPY
Bonds payableCurrentQuarterInstant31100000000JPY
Long term loans payablePrior1YearInstant29000000000JPY
Long term loans payableCurrentQuarterInstant29000000000JPY
Net defined benefit liabilityPrior1YearInstant7174000000JPY
Net defined benefit liabilityCurrentQuarterInstant7278000000JPY
Asset retirement obligations nclPrior1YearInstant1571000000JPY
Asset retirement obligations nclCurrentQuarterInstant1687000000JPY
Provision for share based remuneration nclPrior1YearInstant75000000JPY
Provision for share based remuneration nclCurrentQuarterInstant164000000JPY
Provision for compensation loss nclPrior1YearInstant637000000JPY
Provision for compensation loss nclCurrentQuarterInstant－JPY
Provision for loss on guaranteesPrior1YearInstant699000000JPY
Provision for loss on guaranteesCurrentQuarterInstant20000000JPY
Provision for loss on liquidation of subsidiaries and affiliates nclPrior1YearInstant－JPY
Provision for loss on liquidation of subsidiaries and affiliates nclCurrentQuarterInstant817000000JPY
Other nclPrior1YearInstant14016000000JPY
Other nclCurrentQuarterInstant18193000000JPY
Noncurrent liabilitiesPrior1YearInstant84274000000JPY
Noncurrent liabilitiesCurrentQuarterInstant88262000000JPY
LiabilitiesPrior1YearInstant148344000000JPY
LiabilitiesCurrentQuarterInstant155290000000JPY
Capital stockPrior1YearInstant9279000000JPY
Capital stockCurrentQuarterInstant9279000000JPY
Capital surplusPrior1YearInstant25001000000JPY
Capital surplusCurrentQuarterInstant25001000000JPY
Retained earningsPrior1YearInstant97700000000JPY
Retained earningsCurrentQuarterInstant93273000000JPY
Treasury stockPrior1YearInstant-2256000000JPY
Treasury stockCurrentQuarterInstant-2258000000JPY
Shareholders equityPrior1YearInstant129724000000JPY
Shareholders equityCurrentQuarterInstant125296000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant1498000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant1755000000JPY
Foreign currency translation adjustmentPrior1YearInstant13209000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant10805000000JPY
Remeasurements of defined benefit plansPrior1YearInstant-2014000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant-1871000000JPY
Valuation and translation adjustmentsPrior1YearInstant12692000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant10688000000JPY
Subscription rights to sharesPrior1YearInstant88000000JPY
Subscription rights to sharesCurrentQuarterInstant95000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass